FORTISSIMO study Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide fixed full-dose combination Karpov YA; FORTISSIMO program.

Slides:

Advertisements

Similar presentations

Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.

Advertisements

Analysis of the ADVANCE Trial Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 28, 2008.

Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.

The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.

Valsartan Antihypertensive Long-Term Use Evaluation Results

Robert K Huff PharmD. Candidate May Objectives The study was designed to examine 3 main aspects Biochemical effects Safety Tolerability Evacetrapib.

The Rationale for Initiating Therapy with Fixed-Dose Combinations in Hypertension Thomas D. Giles, M.D. Tulane University School of Medicine New Orleans,

Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.

2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

A MULTICENTRIC PHASE I STUDY OF SUNITINIB WITH CONCOMITANT RADIATION THERAPY IN INOPERABLE SARCOMAS (GIST EXCLUDED) M.P. SUNYACH, D. PEROL, N. PENEL, P.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

HOME AND AMBULATORY BLOOD PRESSURE MONITORING

International Congress Highlights 2004 Clinical Update in GI disease Portal Hypertension P. Michielsen University of Antwerp

Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.

New concept – no traditional combination LODOZ contains Bisoprolol and Hydrochlorothiazide in subtherapeutic dosages: - Bisoprolol 2.5 mg (= half / quarter.

Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.

Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan H Wilke, R Glynne-Jones, J Thaler,

BACLOFEN AS AN ADJUNCT PHARMACOTHERAPY FOR THE MAINTENANCE OF ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS WITH ESTABLISHED LIVER DISEASE Lynn Owens 1, Abi.

Efficacy and Comparability of Thiazide-type Diuretics

A Controlled Trial of Renal Denervation for Resistant Hypertension

Why fixed-dose combinations in hypertension? Barrios V, Escobar C. Integrated Blood pressure Control. 2010: Combination therapy is needed when.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

The Effect of Bimatoprost 0.03% vs Travoprost 0.004% in Patients on Latanoprost 0.005% Requiring Additional IOP Lowering Jeffrey A. Kammer, 1 Barry Katzman,

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Renal denervation for resistant hypertension: it’s time to reconsider!

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Manufacturer: AstraZeneca FDA Approval Date: December 22, 2015

Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.

Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements Reference:

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:

R1. 이용석 / modulator pf. 임천규. Introduction Autosomal dominant polycystic kidney disease (ADPKD) is characterized by gradual cyst enlargement over a period.

Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.

Multicenter, Placebo-Controlled Trial

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

Neal B, et al. Diabetes Care 2015;38:403–411

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

The Anglo Scandinavian Cardiac Outcomes Trial

Diabetes Journal Club Julie Shah.

Hypertension Guidelines

Krop I et al. SABCS 2009;Abstract 5090.

These slides highlight a report based on original presentations at the 24th Meeting of the French Society of Arterial Hypertension (SFHTA) in Paris, France,

Volume 59, Issue 4, Pages (October 2013)

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Managing Blood Pressure

End point Valsartan Valsartan+HCTZ p

Volume 73, Issue 11, Pages (June 2008)

Read more STRIDE BP - Accurate BP Monitors

Role of - Azilsartan - Azilsartan/chlorthalidone

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

FORTISSIMO study Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide fixed full-dose combination Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

Objectives Evaluate the safety and efficacy of the fixed-dose combination perindopril arginine/indapamide (10/2.5 mg) in reaching the blood pressure target In patients with uncontrolled hypertension With previous treatment: fixed or free combination of renin-angiotensin-aldosterone system (RAAS) inhibitors + hydrochlorothiazide (HCTZ) Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

Design and Methods Open, prospective, multicenter, observational, noncomparative study Inclusion criteria: uncontrolled hypertension (160-200 mm Hg) 2120 hypertensive ambulatory patients in 35 regions of Russia 12-week study (5 visits) Switch to drug combination perindopril/indapamide (10/2.5 mg) Assessment of: Office blood pressure dynamics Blood and urine assays Quality of life Treatment compliance Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

Results – Blood pressure Blood pressure significantly decreased over time After 3 months of treatment, 84% of patients reached the blood pressure target Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

Results - Tolerability Treatment compliance significantly increased Only 4% of patients had adverse effects Biochemical markers showed no negative changes Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

Conclusion Rapid and sustained effect with the drug combination perindopril/indapamide (10/2.5 mg) in patients with uncontrolled hypertension 84% of patients reached the blood pressure target Treatment: good tolerability Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.